Belgian neurotechnology business ReVision Implant has closed an oversubscribed funding round of 4 million euros, in a deal that pushes one of Europe’s leading brain-interface centers out of the laboratory and into the early stages of clinical work.
The promotion, taken from private investors, attracted both existing backers and a new group of European business leaders and medtech operators, a mix of investors that often shows more than a passing enthusiasm in a sector where capital has recently been notorious for locking up. It also follows public support which includes a number of competitions within the European Innovation project, Viir2 of the Council project of 4 euros. from Plug & Play and imec.istart incubators.
In a deep-tech business of this class, the combination of liquefied private capital and unmixed EIC support is exactly the financial stack British and European life-science founders have spent 18 months arguing the UK still can’t replicate, a point the magazine explored in its coverage of the UK’s £850m Cambridge life-science deals.
Completely bypassing the eye
The ReVision Implant is a cortical visual prosthesis that aims to restore functional vision to people with severe blindness, including a large group of patients that retinal or optic-nerve therapy cannot help. Rather than trying to fix the eye, the device connects directly to the brain’s visual cortex, avoiding damage that goes down the visual pathway and, in effect, allowing recipients to see and interpret the visual information produced by the external camera.
It’s the kind of high-bandwidth, brain-machine communication work that, until recently, has been considered the preserve of a handful of American firms that hold high-profile titles. Yet science has moved on, and a small number of European competitors, the ReVision Implant among them, are now closing the gap in conditions ranging from quadriplegia and locked-in syndrome to aphasia, amputation and blindness.
Internal manufacturing as a strategic area
Three months ago the company began setting up its own cleanrooms, a deliberate move to bring key manufacturing steps in-house before clinical trials. For a Class III implantable device, production control is not an office detail; it is a regulatory and commercial channel. Taking out all the steps tends to reduce duplication, increase costs and complicate audits, problems that have filled the European medtech hope at the wrong time.
Frederik Ceyssens, CEO of ReVision Implant, said this round marks the point where the business moves from pure development to increased performance. “We are investing in our clean house environment to bring important manufacturing steps in-house, while expanding our team and improving our compliance and clinical program in the coming years,” he said. “At the same time, we are continuing product development and strengthening our partnerships with other medtech companies as we move closer to bringing our technology to patients.”
Advanced appointment and exam for Q3 2026
The funding comes shortly after the US Food and Drug Administration awarded the company Breakthrough Device designation, a status reserved for technologies that address serious or irreversible debilitating conditions, and one that opens up earlier and more frequent interactions with FDA reviewers. With the first phase of its first-in-human study cleared by regulators and penciled in for the third quarter of 2026, the ReVision Implant has the rare luxury of moving into a recognized clinical window with money in the bank.
For investors looking at neurotechnology more broadly, the lesson is clear. The success of recent rounds elsewhere, such as the British Enterprise Bank’s £8m investment in NRG Therapeutics, suggests that appetite for serious science is returning, as headline business funding remains scarce. If the first ReVision Implant patients see anything later this year, the company will find itself at the center of a market that, at variable rates, could one day help millions.
